• <table id="4k0m6"><noscript id="4k0m6"></noscript></table>
    <table id="4k0m6"><noscript id="4k0m6"></noscript></table>
  • <table id="4k0m6"><noscript id="4k0m6"></noscript></table>
  • 公司新聞

    青煜醫藥2018年學術系列講座(一)

      2018年4月18日,青煜醫藥2018年學術系列講座在創想園舉辦。我們非常榮幸地邀請了Alex Matter博士做了題目為‘Personalized anticancer drug discovery & development in Asia’ 的學術講座。


    Dr Alex Matter is CEO of the Experimental Therapeutics Centre since April 2009 and since January 2012 CEO of the newly created D3 platform, A*STAR, Singapore. Previously, he had spent five and a half years as Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009. Prior to this role, Dr. Matter was Global Head of Oncology Research for Novartis Pharmaceuticals Corporation. Dr. Matter played an important role in the success of several anticancer drugs, including Gleevec/Glivec? .


    2.jpg

    公司總經理鄒斌博士對Alex博士的到來表示歡迎并進行了介紹。


    3.jpg

    4.jpg

    Alex博士滿懷激情地分享了藥物研究開發的故事和體會,現場聽眾十分投入。


    5.jpg

    6.jpg

    會后,Alex博士對聽眾提出的問題進行一一答復。


    上一個:No more! 下一個:“青”盡全力,“煜”藥于新>

    新聞分類

    聯系我們

    上海青煜醫藥科技有限公司

    聯系人:林女士

    電話:021-61160506-6121

    zhaopin@blueraybiopharma.com

    地址:上海浦東李冰路576號3號樓1樓